Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT07177079
High-Dose Ascorbate + Azacitidine and Venetoclax
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
83 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Leukemia, lymphoma, and myeloma83 studies
Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT07177079
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
Acute Myeloid LeukemiaPhase 1NCT06152809
CIML NK Cells With Venetoclax for AML
Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMMLPhase 1/2NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
NeoplasmsPhase 1NCT05836896Papers
Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Acute Myeloid LeukemiaPhase 1NCT07439211
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Relapsed or Refractory Aggressive B-Cell LymphomaPhase 1/2NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
HIV-Associated LymphomaPhase 1NCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Acute Myeloid Leukemia, PediatricPhase 1/2NCT06158828
Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
T-cell Acute Lymphoblastic LymphomaPhase 1NCT03081910Papers
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Multiple MyelomaPhase 1NCT05976555Papers
BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Central Nervous System LymphomaPhase 1NCT06607549
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
B-Cell LymphomaPhase 1/2NCT05092451Papers
CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Recurrent Childhood Acute Myeloid LeukemiaPhase 1NCT06609928Papers
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Cutaneous T-Cell Non-Hodgkin LymphomaPhase 1/2NCT03011814Papers
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Phase 1/2NCT01371630Papers
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT04659616Papers
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Non-Hodgkin LymphomaPhase 1NCT05098613Papers
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Multiple MyelomaPhase 1NCT06185751
CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCLPhase 1/2NCT06249191
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
AML or MDS Undergoing Reduced-Intensity TransplantPhase 1NCT06996119
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
High-Risk Acute Leukemia or Myelodysplastic SyndromePhase 1/2NCT03670966
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Acute Lymphoblastic LeukemiaPhase 1/2NCT03128034Papers
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Acute Myeloid LeukemiaPhase 1NCT04024761Papers
CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Acute Myeloid LeukemiaPhase 1NCT06138587
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation